Due Diligence

Technology, market, customers, competitors, business model, regulatory strategy, reimbursement – in the life sciences, you need to go a level deeper to understand the attractiveness and positioning of your target investment. DeciBio can get you there.

Our Experts

David Cavanaugh

David Cavanaugh

Carl Schoellhammer

Carl Schoellhammer

Stephane Budel

Schedule a Call

Related Client Results

All Client Results

Clinical Diagnostics

Carrier Screening Landscape Assessment

A leading diagnostics player wanted an assessment of the current and future carrier screening landscape, primarily in the U.S., to guide their product development strategy

Voice-of-Customer Research

Financial Services

PE-Backed Life Sciences Tools Platform Development

A leading private equity firm and management team sought out DeciBio as a strategic partner to advise on the life sciences market and perform due-diligences in support of the development of a novel life sciences tools platform

Voice-of-Customer Research

Customer Segmentation

Pricing Strategy

Due Diligence

Competitive Analysis

Clinical Diagnostics

Low-Throughput Molecular Diagnostic Testing Landscape Assessment

A leading diagnostic company wanted an assessment of the future market landscape for low-throughput (LT) molecular diagnostic (MDx) testing to develop a long-term platform strategy to address the future needs of this market

Voice-of-Customer Research

Competitive Analysis

Customer Segmentation

Pharma & Biotech

Cell and Gene Therapy Services Landscape Assessment

A top-10 scientific service provider wanted to quantify the size of the CGT services market and understand trends within

No items found.

Methylation Analysis Opportunity Identification for Ultra-Sensitive Detection Platform

A leader in research tools and clinical diagnostic development asked us to evaluate the opportunity for an ultrasensitive detection platform in methylation analysis

Target Identification

Clinical Diagnostics

RNA-based Oncology Biomarker Market Landscape

A cancer diagnostics company wanted to understand the current and future landscape for RNA-based oncology biomarkers, focusing on gene expression profiling (GEP) and rearrangements across medical settings

Voice-of-Customer Research

Competitive Analysis

Biomarker and Diagnostics Strategy

Product Specification Mapping

Precision Medicine is evolving at a rapid pace

Discover how we can help